Tuesday, December 1 | 4:30 p.m.-5:30 p.m. | T8-SSNMMI04-4 | Room S405
Whole-liver uptake on gallium-68 (Ga-68) fibroblast activation protein inhibitor (FAPI) PET increased significantly as fibrosis stage worsened in patients with chronic liver disease, according to a prospective study presented in this session.
In a single-center, IRB-approved study of 30 adults with known or suspected chronic liver disease undergoing clinical liver biopsy, Fatemeh Rashidi, MD, of the University of Wisconsin in Madison, and colleagues imaged patients on a hybrid PET/MRI system (Signa PET/MR, GE HealthCare) following intravenous administration of Ga-68 FAPI-46. PET data was acquired over the liver at 45 minutes post-injection, with average whole-liver FAPI uptake compared against histopathologically confirmed fibrosis stages F0 through F4.
The standardized uptake value normalized to lean body mass (SUVL) increased significantly across fibrosis stages (p = 0.012), and Spearman correlation analysis demonstrated a significant association between SUVL and fibrosis stage (rho = 0.57, p = 0.0008). Patient distribution spanned F0 (n = 3), F1 (n = 6), F2 (n = 13), F3 (n = 5), and F4 (n = 3).
Current elastography-based methods can estimate liver stiffness as a fibrosis surrogate but are limited in detecting early-stage disease and distinguishing fibrosis from active inflammation, the authors noted.
“FAPI-PET provides a promising non-invasive approach for whole-liver fibrosis assessment,” the authors noted.
Finish off the day Tuesday in this late afternoon session to learn more.



